Aspirin resistance and platelet turnover: A 25-year old issue

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 21, Issue 8, 2011, Pages 542-545

  Di Minno, G ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Aspirin resistance; Diabetic angiopathy; Mouse anti thrombotic assay; Pairs of aggregating agents; Platelet turnover; Stored platelets

Indexed keywords

ACETYLSALICYLIC ACID; PROSTAGLANDIN SYNTHASE; THROMBOXANE;

ANIMAL; BIOSYNTHESIS; DIABETIC ANGIOPATHY; DISEASE MODEL; DRUG EFFECT; DRUG RESISTANCE; HUMAN; METABOLISM; SHORT SURVEY; THROMBOCYTE; THROMBOCYTE AGGREGATION;

ANIMALS; ASPIRIN; BLOOD PLATELETS; DIABETIC ANGIOPATHIES; DISEASE MODELS, ANIMAL; DRUG RESISTANCE; HUMANS; PLATELET AGGREGATION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; THROMBOXANES;

EID: 79961127761     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2011.04.002     Document Type: Short Survey

References (35)

1. Di Minno G., Silver M.J., de Gaetano G. Prostaglandins as inhibitors of human platelet aggregation. Br J Haematol 1979 Dec, 43(4):637-647.
2. Grant J.A., Scrutton M.C. Positive interaction between agonists in the aggregation response of human blood platelets: interaction between ADP, adrenaline and vasopressin. Br J Haematol 1980 Jan, 44(1):109-112.
3. Di Minno G., Murphy M.J., Silver S. Stored human platelets: full aggregation potential in response to pairs of aggregating agents. Blood 1982, 59(3):563-568.
4. Di Minno G., Silver M.J. Mouse antithrombotic assay: a simple method for the evaluation of antithrombotic agents in vivo. Potentiation of antithrombotic activity by ethyl alcohol. J Pharmacol Exp Ther 1983 Apr, 225(1):57-60.
5. Catalano P.M., Smith J.B., Murphy S. Platelet recovery from aspirin inhibition in vivo; differing patterns under various assay conditions. Blood 1981, 57(1):99-105.
6. Di Minno G., Silver M.J., Murphy S. Monitoring the entry of new platelets into the circulation after ingestion of aspirin. Blood 1983, 61(6):1081-1085.
7. O'Brien J.R. Effects of salicylates on human platelets. Lancet 1968 Apr 13, 1(7546):779-783.
8. Rao G.H., White J.G. Epinephrine potentiation of arachidonate-induced aggregation of cyclooxygenase-deficient platelets. Am J Hematol 1981, 11:355.
9. Tschoepe D., Roesen P., Esser J., Schwippert B., Nieuwenhuis H.K., Kehrel B., et al. Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Hemost 1991, 17:433-438.
10. van Pampus E.C., Huijgens P.C., Zevenbergen A., Twaalfhoven H., van Kamp G.J., Langenhuijsen M.M. Influence of aspirin on human megakaryocyte prostaglandin synthesis. Eur J Haematol 1993, 50:264-268.
11. Winocour P.D. Platelet turnover in advanced diabetes. Eur J Clin Invest 1994, 24(Suppl. 1):34-37.
12. Di Minno G., Silver M.J., Cerbone A.M., Murphy S. Trial of repeated low-dose aspirin in diabetic angiopathy. Blood 1986, 68(4):886-891.
13. Cerletti C., Carriero M.R., de Gaetano G. Platelet-aggregation response to single or paired aggregating stimuli after low-dose aspirin. N Engl J Med 1986 Jan 30, 314(5):316-318.
14. Akopov S.E., Gabrielian E.S. Synergism between agonists is similar but not identical to that of PRP, and NWB appears to provide a sensitive system with a more physiologic milieu than other in vitro aggregation systems. Effects of aspirin, dipyridamole, nifedipine and cavinton on platelet by different aggregating agents alone and in combination. Eur J Clin Pharmacol 1992, 42(3):257-259.
15. Sturk A., Asyee G.M., Schaap M.C., van Maanen M., ten Cate J.W. Synergistic effects of platelet-activating factor and other platelet agonists in human platelet aggregation and release: the role of ADP and products of the cyclooxygenase pathway. Thromb Res 1985, 40(3):359-372.
16. Boyd D.G., Davis R.B. Observations on human platelet aggregation in native whole blood (NWB): synergism and sensitivity to aggregating agents in vitro. Thromb Res 1988, 50(3):429-436.
17. de Gaetano G., Cerletti C. Aspirin resistance: a revival of platelet aggregation tests?. J Thromb Haemost 2003, 1:2048-2050.
18. Halushka M.K., Halushka P.V. Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2?. Circulation 2002, 108:1620-1622.
19. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 2003, 1:1710-1713.
20. Cambria-Kiely J.A., Gandhi P.J. Aspirin resistance and genetic polymorphisms. J Thromb Thrombolysis 2002, 14:51-58.
21. Halushka M.K., Walker L.P., Halushka P.V. Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin Pharmacol Ther 2003, 73:122-130.
22. Gum P.A., Kottke-Marchant K., Welsh P.A., White J., Topol E.J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003, 41:961-965.
23. Pulcinelli F.M., Pignatelli P., Celestini A., Riondino S., Gazzaniga P.P., Violi F. Inhibition of platelet aggregation by aspirin progressively decrease in long-term treated patients. J Am Coll Cardiol 2004, 43:1122-1126.
24. Lee P.Y., Chen W.H., Ng W., Cheng X., Kwok J.Y., Tse H.F., et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med 2005, 118:723-727.
25. Baigent C., Blackwell L., Collins R., Emberson J., Godwin J., Peto R., et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009, 373:1849. Antithrombotic Trialists' (ATT) Collaboration.
26. Coccheri S. Antiplatelet drugs-do we need new options? With a reappraisal of direct thromboxane inhibitors. Drugs 2010 May 7, 70(7):887-908.
27. Watala C., Golanski J., Pluta J., Boncler M., Rozalski M., Wieclawska B., et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)- its relation to metabolic control. Thromb Res 2004, 113:101-113.
28. Di Minno G., Violi F. Aspirin resistance and diabetic angiopathy: back to the future. Thromb Res 2004, 113:97-99.
29. Grove E.L., Hvas A.M., Mortensen S.B., Larsen S.B., Kristensen S.D. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. J Thromb Haemost 2011, 9:185-191.
30. Eikelboom J.W., Hirsh J., Weitz J.I., Johnston M., Yi Q., Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002, 105:1650-1655.
31. Rocca B., Secchiero P., Ciabattoni G., Ranelletti F.O., Catani L., Guidotti L., et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA 2002, 99:7634-7639.
32. Weber A.A., Zimmermann K.C., Meyer-Kirchrath J., Schror K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 1999, 353:900.
33. de Gaetano G., Cerletti C., Dejana E., Latini R. Pharmacology of platelet inhibition in humans: implications of the salicylate-aspirin interaction. Circulation 1985 Dec, 72(6):1185-1193.
34. Fitzgerald G.A. Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol 1991, 68:5B-11B.
35. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Trialists' Collaboration. Br Med J (Clin Res Ed) 1988, 296(6618):320-331.